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Summary
Many effective anti-cancer strategies target apoptosis and angiogenesis mechanisms. Applications of non-ioniz-
ing, nanosecond pulsed electric fields (nsPEFs) induce apoptosis in vitro and eliminate cancer in vivo; however
in vivo mechanisms require closer analysis. These studies investigate nsPEF-induced apoptosis and anti-
angiogenesis examined by fluorescent microscopy, immunoblots, and morphology. Six hours after treatment
with one hundred 300 ns pulses at 40 kV ⁄ cm, cells transiently expressed active caspases indicating that
caspase-mediated mechanisms. Three hours after treatment transient peaks in Histone 2AX phosphorylation
coincided with terminal deoxynucleotidyl transferase dUTP nick end labeling positive cells and pyknotic nuclei,
suggesting caspase-independent mechanisms on nuclei ⁄DNA. Large DNA fragments, but not 180 bp fragmen-
tation ladders, were observed, suggesting incomplete apoptosis. Nevertheless, tumor weight and volume
decreased and tumors disappeared. One week after treatment, vessel numbers, vascular endothelial growth
factor (VEGF), platelet derived endothelial cell growth factor (PD-ECGF), CD31, CD35 and CD105 were decreased,
indicating anti-angiogenesis. The nsPEFs activate multiple melanoma therapeutic targets, which is consistent
with successes of nsPEF applications for tumor treatment in vivo as a new cancer therapeutic modality.
Introduction
Many chemotherapeutic and ionizing radiation treat-
ments demonstrate anticancer efficacy, but efforts must
continue to find new approaches to address cancer dis-
eases. Six major hallmarks of cancer have been outlined
as physiological anomalies that are common to all can-
cers (Hanahan and Weinberg, 2000) and serve as thera-
peutic targets. These include evading apoptosis, self
sufficiency in growth signals, insensitivity to anti-growth
Significance
Skin cancer is widespread and metastatic melanoma, which is resistant to a wide range of treatment
modalities, is the most deadly. Nanosecond pulsed electric fields (nsPEFs) eliminate melanoma by apply-
ing extremely brief and intense electric fields, which are high in power but low in thermal energy. The
nsPEFs interact with multiple intracellular and plasma membrane structures ⁄ functions including apop-
tosis and anti-angiogenesis mechanisms, both major cancer treatment targets. Applications of nsPEFs are
expected to be safe and non-toxic. They can probably be applied using local anesthetic alone or in com-
bination with other treatment modalities and with development of catheter electrodes they can probably
be used to treat internal organs with laparoscopic surgery.
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signals, sustained angiogenesis, limitless replicative
potential, and tissue invasion and metastasis. Kroemer
and Pouyssegur (2008) added evading immune surveil-
lance as a seventh cancer hallmark. While many of
these hallmarks have been addressed with therapeutic
strategies, a number of therapies have focused on acti-
vating apoptosis and inhibiting angiogenesis. These
include using monoclonal antibodies, recombinant
ligands, RNA interference and small molecule anta-
gonists ⁄ agonists. However, some of these may pro-
mote cellular compensation that leads to resistances
and reoccurrences (Fesik, 2005; Letai, 2008). Although
cancer death rates have begun to slowly decrease, met-
astatic melanoma is one of the most resistant cancers.
It is appropriate to find alternative treatments and to
look beyond pharmaceutical methodologies.
Some alternative therapeutic approaches in clinical
trials use physical methods because they locally
treat tumors without systemic disturbances. Two such
methods, cryotherapy and radiofrequency ablation, use
extreme temperatures to induce frank necrosis including
(Bland et al., 2007). Several new strategies use electric
fields to eliminate cancer. One approach in clinical trials is
electro-gene therapy, which uses conventional electro-
poration (EP) to deliver genes that locally activate immune
mechanisms against melanoma (Daud et al., 2008).
Another EP technology in clinical application is electr-
ochemotherapy, which delivers impermeable chemother-
apeutic drugs to tumors (Gehl, 2008; Heller et al., 1996;
Mir et al., 1991). Another physical approach is irreversible
EP, which extends EP conditions to fatally damage
tissues (Davalos et al., 2005; Lee and Kolodney, 1987;
Lee et al., 2000; Maor et al., 2009; Onik et al., 2007).
Another emerging alternative non-drug, non-thermal
method extends EP using ultrashort, intense pulsed elec-
tric fields with nanosecond durations (nsPEFs) as a non-
ionizing means to treat cancer (Beebe et al., 2002,
2003a, 2004; Nuccitelli et al., 2006, 2009). This pulse
power technology, initially developed for aerospace and
military purposes, has recently crossed disciplines find-
ing potential applications in biology and medicine. Both
modeling evidence in vitro (Gowrishankar and Weaver,
2006; Gowrishankar et al., 2006; Hu et al., 2005; Stewart
et al., 2004; Vernier et al., 2006) and in vivo (Esser et al.,
2009; Gowrishankar et al., 2006; Joshi et al., 2007) and
experimental evidence (Schoenbach et al., 2001; Tekle
et al., 2005; White et al., 2004) indicate that the larger
nsPEFs induce intracellular membrane charging events,
which are absent during EP. Further, these same studies
indicate that nsPEFs produce nanopores (1 nm) in all
cell membranes, including plasma membranes (Pakho-
mov et al., 2009). These differences from EP provide
new possibilities for unique cellular effects and some of
these may have clinical relevance in cancer (Beebe et al.,
2002, 2003a,b, 2004; Chen et al., 2009; Garon et al.,
2007; Nuccitelli et al., 2006, 2009) wound healing (Zhang
et al., 2008) and cardiovascular medicine (Wang et al.,
2009). Thus, EP technology has branched into a number
of potentially important clinical cancer applications for
gene delivery, drug delivery (electrochemotherapy), irre-
versible EP and nsPEFs.
The pervasive effects induced by nsPEFs on cell
structures and subsequent functions provide potentials
for therapeutic applications. One investigated response
to nsPEFs (Beebe et al., 2003a,b, 2004; Ford et al., 2010;
Hall et al., 2007a) is the appearances of characteristics of
apoptosis (Kroemer et al., 2009). In vivo studies have
shown nsPEFs to reduce fibrosarcoma tumor size
(Beebe et al., 2002, 2003a, 2004), to eliminate B16f10
melanoma in mice without reoccurrence (Nuccitelli et al.,
2006, 2009) and to eradicate a human basal cell carci-
noma (Garon et al., 2007). We investigated in detail
nsPEFs on in vivo mechanisms that permanently remove
B16f10 melanoma tumors without reoccurrence in a
mouse model (Nuccitelli et al., 2009). The results indicate
that nsPEFs target two of the seven cancer hallmarks
(Hanahan and Weinberg, 2000; Kroemer and Pouyssegur,
2008) on solid B16f10 melanoma tumors, including
apoptosis evasion and sustained angiogenesis, which is
critical for a third hallmark, invasion and metastasis.
Results
Tumors were treated in vivo with 100 pulses at 300 ns
and 40 kV ⁄ cm and analyzed for the presence of Histone
2AX phosphorylation (cH2AX), terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) and active
executioner caspase-positive tumor cells in the first
hours (1, 3, 6 and 24 h) after treatment. Representative
experiments are illustrated in Figure 1 and statistical
analyses in Figure 2.
nsPEFs induce DNA double stranded breaks
The presence of cH2AX immunofluorescent staining was
used as a sensitive and early monitor to identify DNA at
double strand breaks (Bonner et al., 2008; Rogakou et al.,
1999) in nsPEF-treated B16f10 tumors in vivo (Figures 1
and 2). Figure 1 shows time-dependent increase in
cH2AX in melanoma, with significant differences occur-
ring at 1 h, reaching a peak at 3 h and decreasing to
control levels thereafter. A quantitative analysis of cH2AX
illustrated in Figure 2 shows that 15, 85, 5 and 5% of
B16f10 tumors cells exhibited cH2AX at 1, 3, 6 and 24 h,
respectively, after nsPEF treatment.
nsPEFs induce DNA damage determined by TUNEL
and agarose gel electrophoresis
Terminal deoxynucleotidyl transferase dUTP nick end
labeling is used to define DNA damage and fragmenta-
tion as an apoptosis marker (Kroemer et al., 2009). In
Figure 1, nsPEF treatment of B16f10 tumors in vivo
resulted in significant increases TUNEL positive cells at
3 h post-pulse with a peak near 6 h and decreases by
24 h. Figure 2 indicates that 7, 27, 43 and 3% of
nsPEFs targets apoptosis and angiogenesis
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B16f10 tumor cells were TUNEL positive 1, 3, 6 and
24 h, respectively, after nsPEFs treatment.
To determine whether DNA fragmentation occurred
after nsPEF treatment, DNA was extracted from tumors
and analyzed by electrophoresis on ethidium bromide-
stained agarose gels for multiples of 180 bp frag-
ments. Typical DNA fragmentation ladders were not
present at any times tested. Degraded DNA was
observed as large fragments at 6 h and significant DNA
smearing at 24 h post-pulse (data not shown).
nsPEFs activate executioner caspases
Immunofluorescent staining for executioner (also called
effector) caspase, which cleave cellular proteins to initi-
ate the apoptosis process, was determined using a mix-
ture of antibodies to active caspase-3, -6, and -7 in
melanomas at times after nsPEF treatment (Figures 1
and 2). Time courses indicated that percentages of cas-
pase positive cells significantly increased 3 h post-pulse,
peaked near 6 h, and then decreased by 24 h. A quanti-
tative analysis of active caspases shown in Figure 2 indi-
cated that 5, 28, 43 and 3% were present 1, 3, 6 and







Figure 1. Immunofluorescent staining of
cH2AX, terminal deoxynucleotidyl
transferase dUTP nick end labeling
(TUNEL) and executioner (-3, -6, and -7)
caspase positive B16f10 melanoma tumor
cells after treatment with nanosecond
pulsed electric fields. B16f10 tumors were
treated with one hundred 300 ns pulses at
40 kV ⁄ cm. One, 3, 6 and 24 h later
tumors were removed and prepared for
immunofluorescent histology.
Representative fluorescent images from
each fluorescent antibody condition are
shown. Six different mice were used at
each time point and each experiment was
repeated twice (12 tumors). The cH2AX-,
TUNEL- and caspase-positive signals are
indicated by green fluorescence in
contrast to propidium iodide red
fluorescence-stained nuclei. Merged
































Figure 2. A composite graphic kinetics of DNA damage and
apoptosis in the first 24 h after treatment with nanosecond pulsed
electric fields. Tumors were treated in vivo, removed at various
times and analyzed for immunofluorescent changes in cH2AX,
terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) and executioner caspase-3, -6, and -7. Six different mice
were used at each time point and each experiment was repeated
twice (12 tumors). The results represent the mean ± SD.
Significant increases for H2AX at 1 and 3 h and for TUNEL and
caspase at 3 and 6 h were P < 0.001 versus control.
Chen et al.
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Effects of nsPEFs on nuclear morphology
To determine morphological effects on B16f10 nuclei,
the nuclear areas were measured after H&E staining at
various times after nsPEF treatment (Figure 3). Control
tumor cells exhibited light staining pleomorphic nuclei
and abundant cytoplasm containing finely dispersed mel-
anin granules. Treated tumors exhibited dense staining,
condensed and elongated nuclei. In contrast, treated
melanomas exhibited individual cells scattered from
tumor cords with coarse intracellular melanin granules
and aggregated extracellular melanin granules. Quantita-
tive comparisons were made by calculating mean
nuclear area (lm2) between control melanomas and
treated tumors during the first 24 h post-nsPEF treat-
ment. Significant differences were observed between
control and all post-treatment times (Figure 3).
Tumor weight decreases after nsPEF treatment
Prior to treatment with nsPEFs melanomas grew to
similar weights 6 d after B16f10 tumor initiation (control
group 1.45 ± 0.15 versus treated group 1.59 ± 0.12).
One day after nsPEF treatment, treated tumors (1.41 ±
0.18) became slightly smaller than control tumors
(1.61 ± 0.25), which increased slightly. One week later,
tumors without nsPEF treatment increased twofold in
weight (2.71 ± 0.17) while treated tumors decreased in
weight (0.58 ± 0.21) about threefold.
nsPEFs decrease pre-existing blood supply
As melanoma tumors developed to 5–7 mm2, a rich
blood supply to the tumors with branching vessels was
seen by transillumination. In untreated tumors primary
and secondary vessels feeding the tumor increased 43,
71, 85 and 100% on days 1, 2, 7, 14, and 17, respec-
tively. In treated tumors, the number of feeding vessel
did not decrease until between days 3 and 7. At day 7,
vessel numbers were 16% of the same day control. On
days 14 and 17, the numbers of vessels feeding the
tumor were less than 1% of controls (data not shown).
The vessel numbers within tumors were counted fol-
lowing H&E staining (Figure 4). In untreated tumors,
angiogenesis produced expanding endothelial plexuses
in red (Figure 4A, B). A decrease in vessel numbers
within tumors did not decrease until between days 3
and 7. The decrease in vessel numbers feeding tumors
was 33, 50, and 68% on days 7, 14, and 17. In the trea-
ted tumors on day 1 and day 2 post-nsPEF treatments,
the vasculature still consisted of a fine, reticulated net-
work of small diameter vessels which stained red. On
days 7 and 14 vessel numbers decreased dramatically
Control T1 h T3 h
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Figure 3. Tumor construction and nuclear shape changes 1–24 h post-nanosecond pulsed electric field treatment. Tumors were treated in
vivo with 100 pulses at 300 ns and 40 kV ⁄ cm. Tumors were removed 1, 3, 6, and 24 h post-pulses and prepared for H&E staining.
Representative samples are shown with 1000· magnification and typical nuclei are outline in yellow. Specimens were randomly analyzed and
mean nuclei areas were measured from six mice for each time point and shown in the bar graph with mean and SE using a computer-
assisted interactive image analysis system MATLAB. Nuclear areas were estimated after manual editing of binary images. There were significant
differences between the control and 1, 3, 6, and 24 h post-pulses (P < 0.001) as well as between 1 and 3 h (P < 0.001).
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with decreased tumor size. On day 17 after nsPEF treat-
ment, tumors shrank to a mass of melanin without red
stained vessel lumens. In untreated tumors, growth
was accompanied by increased vascularity; the vessel
numbers on days 1, 2, 7, 14, and 17 d after nsPEF treat-
ment were significantly increased.
Vascular endothelial growth factor (VEGF) and
platelet derived endothelial cell growth factor
(PD-ECGF) protein expression were decreased
by nsPEF treatment
Neo-vascular markers were assayed including expres-
sion of VEGF and PD-ECGF by immunoblot analysis
from four tumors from different mice. Both VEGF and
PD-ECGF protein expression decreased after nsPEF
treatments compared to controls (Figure 5).
nsPEFs inhibit micro-vessel density (MVD)
Common angiogenesis MVD were evaluated by expres-
sion of CD31, CD34, and CD105. CD31 is a platelet-
endothelial cell adhesion molecule used as a pan-endo-
thelial cell marker. CD34 is an endothelial cell marker.
CD105 is a proliferation-related endothelial cell marker.
Figure 6 shows typical immunohistochemical expres-
sion patterns for each MVD marker. In all three stains,
control tumors showed red stained areas indicating the
presence of intensive endothelium in neovascular hot
spots. Upon high power analysis, red stained areas
were seen as endothelial cells or clusters clearly sepa-
rate from adjacent non-stained tumor cells. In contrast,
treated tumors showed significantly attenuated levels
of endothelium. A quantitative analysis of MVD mark-
ers 1 week after nsPEF treatment indicated greatly
significantly reduced staining for all three MVD markers
(Figure 6).
Discussion
These studies present a thorough and coordinated
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Figure 4. Quantitative analysis of vasculature changes within B16f10 melanoma tumors after the nanosecond pulsed electric field (nsPEF)
treatment. Treated tumors were removed on days 1, 2, 7, 14 and 17 after treatment with nsPEFs, shown as T1, T2, T7, T14, and T17; C1
represents control (untreated) tumor. Tumor slides were stained with H&E and tumor vessels were counted by the number of vessel lumen
exhibiting red endothelial plexuses (Image Tool; University of Texas, San Antonio, TX, USA). Vessels were counted on areas of 0.74 mm2 per
field on 10 different slides from each sample.
Chen et al.
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mechanisms for nsPEF-induced cell death in murine
B16f10 melanoma (Chen et al., 2009; Nuccitelli et al.,
2006, 2009). Both apoptosis and angiogenesis are tar-
gets for treatment of cancer cells that establish a niche,
perpetuate mass, and construct tumors using host
blood supplies. Unlike chemotherapeutic agents, which
have systemic effects, nsPEFs are applied as a local
treatment, with cells affected depending on the elec-
trode design and pulsing conditions in a treatment zone.
There are different sensitivities to nsPEFs for cell types
(Beebe et al., 2004; Hair et al., 2003; Stacey et al.,







Figure 5. Effect of nanosecond pulsed
electric fields (nsPEFs) on vascular
endothelial growth factor (VEGF) and
PD-ECGF expression after treatment with
nsPEFs. VEGF and PD-ECGF protein
expression were analyzed by Immunoblot.
Three mice bearing control tumors and
treated tumors were euthanized 7 d after
treatment with nsPEFs. Three control
tumors and four treated tumors were



































Figure 6. Effect of nanosecond pulsed electric fields (nsPEFs) on micro-vascular density (MVD) by CD31, CD34 and CD105: Top panels and
the lower left panel show representative immunohistological staining of MVD markers 7 d after treatment with nsPEFs. The lower right
shows quantitative analyses of MVD markers 7 d post-treatment by counting in five different random fields showing the mean and SD. CD-31
(**P < 0.0001); CD34 (**P < 0.0001) and CD105 (*P < 0.05).
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of these may have clinical significance. When pulsing
conditions reach a cell death threshold, all cells within a
treatment zone can be eliminated, including cancer
cells, cancer stem cells and corrupted host cells
collaborating with tumor cells. This may afford advanta-
ges to nsPEFs, since chemotherapeutic agents and ion-
izing radiation selectively affect proliferating cancer cells
and normal proliferating cells, which cause toxic side
effects. Mechanisms for nsPEF-induced tumor cell
death include caspase-associated apoptosis and cas-
pase-independent apoptosis as well as anti-angiogenic
effects as tumors shrink.
Induction of caspase-associated apoptosis appears to
be an early nsPEF-induced mechanism that promotes
tumor demise as indicated by activation of executioner
caspases, which remain active for more than 6 h after
treatment. However, apoptosis does not go to comple-
tion as indicated by the presence of large DNA frag-
ments and absence of 180 bp DNA fragments on
agarose gels, a late stage apoptosis marker (Kroemer
et al., 2009). Treated tumor weight decreases by only
10% during the first day. However, with large num-
bers of caspase substrates (Fischer et al., 2003) and
rapidity of apoptosis (Green, 2005), it is anticipated
that substantial disassembly takes place, providing a
potential advantage for eventual tumor removal. An in
vivo tumor mass is too substantial to be removed
quickly by natural endogenous apoptosis mechanisms.
Nevertheless, tumor masses decreased after treatment
until the tumors were essentially absent within
2–3 weeks.
The inability to remove apoptosing cells leads to sec-
ondary necrosis with at least two outcomes (Silva et al.,
2008). Leakage of cytosolic contents can lead to inflam-
mation and tissue damage, which is avoided by removal
of apoptosing cells. However, in the case of cancer, this
takes place within the tumor mass. Likewise, secondary
necrotic cells can be taken up by antigen presenting
cells, which provides a possibility for immunity. While
both outcomes may be advantageous, immunity is
rarely realized as a consequence of cancer treatment,
but not unprecedented (Daud et al., 2008).
While nsPEFs induce DNA damage (Beebe et al.,
2002, 2003a, 2004; Nuccitelli et al., 2006, 2009), cause
and effect relationships between active caspases and
DNA damage have not been established. Morphologic
and molecular evidence suggests that initial DNA dam-
age is caspase-independent. Pyknosis, chromosomal
condensation, cH2AX and TUNEL positive cells were
present before caspase activation reached its peak.
Although cH2AX serves as assembly foci for recruit-
ment of DNA repair mechanisms (Shiloh, 2003), DNA
double stranded breaks were identified but not
repaired. Early DNA damage does not appear to be a
caspase-associated apoptosis marker. However, the
mechanism(s) remain to be defined. The nsPEFs do not
generate sufficient energy to break hydrogen bonds and
nsPEFs are not expected to generate reactive oxygen
species (ROS) through ionization of water. Moreover,
ROS in B16f10 cells exposed to nsPEFs in vitro were
absent (Ford et al., 2010). Since ATM (ataxia telangiecta-
sia mutated) and ATR (ATM and Rad 3-related) kinases
are activated with ionizing radiation and UV light (Christ-
mann et al., 2003), knowing the kinase(s) responsible
for cH2AX would shed new light on the mechanism(s)
for nsPEF-induced DNA damage.
Available data suggest that nsPEF-induced DNA dam-
age is not likely a major cause of caspase-associated
apoptosis. First the presence or absence of p53, which
regulates transcription-dependent and independent
events in response to DNA damage (Sheikh et al.,
1998), did not influence survival in HCT116 colon carci-
noma cells after nsPEF treatment (Hall et al., 2007a).
Second, it is likely that transcription events may be irrel-
evant in response to nsPEFs, because nsPEF-induced
cell death ensues very rapidly (Ford et al., 2010; Nucci-
telli et al., 2006) and apoptosis can initiate without
transcription. Finally, p53 responses are mediated by
mitochondria release of pro-apoptotic factors, which
were not evident in nsPEF-treated cells in vitro (Ford
et al., 2010). This remains to be determined in vivo.
One DNA damage mechanisms could be due to activa-
tion of LEI (leukocyte elastase inhibitor) ⁄LEI-derived
DNase II resulting in caspase-independent apoptosis
with activation of other proteases (Torriglia and Lepre-
tre, 2009). This mechanism is consistent with caspase-
independent DNA damage and absences of 180 bp
DNA fragments.
Other effects of nsPEFs on DNA and nuclei have
been reported as disruption of intra-chromatin granule
clusters, suggesting modulation of pre-mRNA splicing
mechanisms (Chen et al., 2007). Another possibility is
that nsPEFs could disrupt the integrity of dynamic cap-
ping structures at chromosome ends, unmasking them,
which could appear as damaged DNA (Deng and
Chang, 2007). These could be caused by nsPEF-
induced conformational changes. Further studies are
necessary to determine nsPEF-induced DNA damage
mechanism(s).
A second nsPEF therapeutic target is angiogenesis.
First, there is significant effects on tumor blood vessels
within the treatment zone (Nuccitelli et al., 2006; this
study) causing a near immediate tumor infarction. Sec-
ond, a decrease in vessel numbers supplying tumors is
coincident with decreased tumor masses, suggesting
tumor-driven angiogenesis. Third, 1 week after treatment
there are diminished levels of VEGF, the most ubiquitous
pro-angiogenic factor. Vascular endothelial growth factor
is a requirement for the angiogenic switch, is a limiting
factor for multistage carcinogenesis (Hanahan and Wein-
berg, 2000) and is induced under ischemic conditions
(Bergers and Benjamin, 2003). This is clearly a harbinger
for the absence of revascularization and renewed tumori-
genesis. This is borne out by elimination of melanoma
Chen et al.
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and absences of reoccurrences (Nuccitelli et al., 2009).
Reduced levels of PD-ECGF, a well known chemotactic
factor for vascular endothelial cells, provide further evi-
dence that nsPEFs deplete the melanoma environment
of needed angiogenic factors. Moreover, there are signif-
icant downstream VEGF effects with reductions in MVD
markers CD31, CD34, and CD105. This is consistent with
findings that while melanoma tumors shrink and vessel
numbers are significantly reduced, formation of new ves-
sels is significantly inhibited. These data indicate that
nsPEFs have profound effects to discourage tumor for-
mation and revascularization.
The nsPEF treatment affected both immediate and
delayed blood vessel effects, most likely by different
mechanisms. One of these could be due to direct elec-
tric field-mediated formation of nanopores in fragile
endothelial cell membranes in capillaries and small blood
vessels. Delayed effects could be due to death of tumor
cell-supported angiogenesis, caspase-associated apopto-
sis and ⁄or deleterious effects on vasa vasorum, small
blood vessels that supply large vessels.
The nsPEFs provide a unique electrical-biological inter-
face using high power and low energy to affect plasma
membranes and intracellular membranes (this study,
Beebe et al., 2002, 2003a,b, 2004). It provides a highly
localized treatment that specifically targets entire mela-
noma tumors within an effective electric field to induce
apoptosis, tumor infarction and prevent angiogenesis.
Other advantages of nsPEFs include insignificant ther-
mal effects (Nuccitelli et al., 2006), which differentiate it
from cryotherapy and radiofrequency ablation. Further,
while surgical resections are common for superficial
melanoma, applications of nsPEFs did not leave scars
on mice (Nuccitelli et al., 2006) or on human skin
(unpublished clinical study). The nsPEFs completely
eliminated mouse B16f10 melanoma in vivo (Nuccitelli
et al., 2006, 2009; this study) and effectively induced
apoptosis and induced apoptosis in a number of cancer
cell lines in vitro (Beebe et al., 2002, 2003a,b, 2004;
Ford et al., 2010; Hall et al., 2007a; Nuccitelli et al.,
2009; Vernier et al., 2003). The nsPEFs can treat
tumors on external body surfaces with needle or plate
electrodes and with the development of catheter elec-
trodes internal organs can likely be treated with laparo-
scopic surgery. This therapy aims for well characterized
cancer therapeutic targets including caspase-associated
and caspase-independent apoptosis mechanisms as
well as anti-angiogenesis, which influences invasion and
metastasis. These studies provide answers to basic
mechanistic questions of nsPEF-induced melanoma cell
death; however, they present new questions regarding
mechanism(s) for DNA damage, relative roles for cas-
pase-associated apoptosis, caspase-independent apop-
tosis, and anti-angiogenic mechanisms for tumor death.
Fewer questions can be raised about the potential for




Murine melanoma B16-F10 cells were obtained from ATCC
(Manassas, VA, USA) and cultured as previously described (Nucci-
telli et al., 2006).
Animals
In vivo experiments conformed to IACUC guidelines under applica-
ble international laws and policies through Eastern Virginia Medical
School. Hairless, female SKH-1 mice were injected subcutaneously
with 100 ll PBS containing 1 · 106 B16-F10 cells. Two tumors
induced simultaneously on the back of each mouse were randomly
selected as either control or treated tumor. Treated tumors were
exposed to nsPEFs using plate electrodes; control tumors were
not. Tumors were removed at various times after treatment. Con-
trol and treated tumors were studied at each time (n = 6).
In vivo imaging
Before and after the treatment, melanomas were imaged daily by
both transillumination and surface photography at 1.2· magnifica-
tion. Tumor volumes were calculated using the formula for prolate
spheroids (square of the width · length · 0.52): V = 0.52 · (D1 ·
D2)2, where D1 and D2 are short and long tumor diameters,
respectively in vivo using transillumination and surface photogra-
phy. Volumes were confirmed by ultrasound.
nsPEF treatment
A pulser used a Blumlein line configuration and was designed and
assembled at the Frank Reidy Research Center for Bioelectrics. It gen-
erated 300 ns pulses with a 30-ns rise time. One hundred pulses were
applied to the treated tumor at 40 kV ⁄ cm and 0.5 Hz. The electrodes
for electric field application, pulse generator, voltage and pulsing pat-
tern of nsPEF were described previously (Nuccitelli et al., 2006).
Histology study
After nsPEF treatments both control and treated tumor were
removed and fixed in 10% neutral buffered formalin prior to paraffin
processing. Sections were stained with H&E and assessed micro-
scopically for abnormal nuclear formation. One hundred nuclei were
randomly selected and outlined in ten non-overlapping fields of each
section. The area of nuclei was measured by the software MATLAB
(The MathWorks, Natick, MA, USA) and summed as the
mean ± SD for statistic analysis.
Tumor blood vessel analysis
Blood vessels (capillaries and venules) were counted in paraffin
embedded tissue sections that were stained by H&E. The vessels
were counted in an area of 0.74 mm2 per field. Any red stained endo-
thelial cells or endothelial clusters with the obvious lumen, clearly
separate from immediately adjacent tumor cells and other connective
tissue elements were considered a single vessel. Neither red blood
cells nor vessel lumens were considered necessary for a structure to
be defined as a vessel. Results were expressed as the highest num-
ber of vessels identified and counted within any single field.
DNA fragmentation
DNA was extracted by standard proteinase K and phenol ⁄ chloro-
form. Electrophoresis was performed in 1.8% agarose gel in TBE
buffer (Tris-borate 89 mM, pH 8.3, EDTA 2 mM) at 30 V for 1 h.
The DNA was visualized by ethidium bromide staining. B16-F10
cells incubated with etoposide (Calbiochem, San Diego, CA, USA)
used as apoptosis positive control.
nsPEFs targets apoptosis and angiogenesis
ª 2010 John Wiley & Sons A/S 561
Immunofluorescent staining
Tumor sections were de-paraffinized and boiled in citrate buffer (pH
6.0) for 5 min for antigen retrieval. The tissue sections were placed
in 3% hydrogen peroxide for 10 min to inactivate endogenous
peroxidase. Tissues were blocked with goat serum, and incubated
in a humidity tray with antibodies against phospho-histone H2AX
(S139) (R&D Systems, Minneapolis, MN, USA; 1:500 dilution), cas-
pase 3 (Cell Signaling Technology, Boston, MA, USA; 1:500 dilu-
tion), caspase 6 (Cell Signaling; 1:800), caspase 7 (BioVision,
Mountain View, CA, USA; 1:400 dilution) for 2 h at room tempera-
ture. Caspase antibodies were used simultaneously. This was fol-
lowed by incubation of a secondary antibody, Alexa Fluor-488-
labeled goat anti-rabbit IgG (Invitrogen, Carlsbad, CA, USA; 1:250
dilution) for 30 min at room temperature in darkness. Cover slips
were mounted with mounting media (Vector Laboratories, Burlin-
game, CA, USA), which contained DAPI (4¢-6-diamidino-2-phenylin-
dole) to identify the nuclei. Numbers of positive cells were
determined by MATLAB software. Three sets of at least 100 cells
under the microscope. Each experiment was performed twice.
TUNEL assay
Terminal deoxynucleotidyl transferase dUTP nick end labeling assay
was done according to the protocol with ApopTag RedTM in Situ
(Chemicon, Temecula, CA, USA). Cells with TUNEL-positive nuclei
with a cytoplasmic halo were counted as indicated above. For neg-
ative controls, no terminal transferase was added. Positive cells
were determined by MATLAB software.
Immunoblot analysis
Proteins were resolved on 15% SDS-polyacrylamide gels and trans-
ferred to polyvinylidene difluoride (PVDF) membrane. Blots were
pre-incubated in blocking buffer (5% non-fat dry milk, 1% Tween
20, in 20 mM TBS pH 8.0) for 1 h at room temperature, incubated
with primary antibodies for VEGF (Santa Cruz, 1:200) or PD-ECGF
(Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA; 1:200 dilu-
tion) in blocking buffer overnight at 4C followed by incubation with
anti-rabbit or anti-mouse secondary antibodies conjugated with
horseradish peroxidase and detected by chemiluminescence and
autoradiography using X-ray film.
Micro-vessel density measurement by CD31, CD34
and CD105 with immunohistochemistry (IHC)
The 5-lm-thick sections were deparaffinized in xylene, rehydrated
and treated with 3% hydrogen peroxide for 20 min. Primary anti-
bodies were used at following dilutions: monoclonal rat-anti-mouse
CD31 (or PECAM-1, BD PharMingen), 1:50; rabbit polyclonal anti-
CD34 (Biovision), 1:250; rat anti-CD105 (BD Pharmingen, San
Diego, CA, USA; 1:200 dilution). Sections were covered with HRP-
conjugated antibodies directed against rat or rabbit immunoglobulin.
Non-specific staining was controlled by incubation with mouse or
rabbit immunoglobulin instead of the specific primary antibody. 3-
amino-9-ethyl-carbazole (AEC) was used as a chromogen, providing
red depositions in situ.
Statistical analysis
Quantitative analysis was based on nuclear areas and positive
immune-stained cells for phospho-H2AX, caspase and TUNEL
between tumors with and without nsPEFs treatment. Samples
were counted by MATLAB software using fluorescent staining. The
number of positive cells was scored by counting three sets of at
least 100 cells under a microscope. The differences between trea-
ted and control groups tested with two-tailed Student’s t test and
analysis of variance (ANOVA) (SPSS Statistical Program 15.0; SPSS
Inc., Chicago, IL, USA).
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